Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16674533 | 1.00 | CES2 (0.50) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL1228934 | 1.00 | CES2 (0.50) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL1911562 | 0.97 | CES2 (0.46) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL2600355 | 0.92 | — | — | |
| SCHEMBL800709 | 0.86 | — | — | |
| SCHEMBL21099805 | 0.86 | MAPT (0.33) | CES2CES1ALDH1A1 | |
| SCHEMBL13197315 | 0.86 | MAPT (0.33) | CES2CES1ALDH1A1 | |
| SCHEMBL21100159 | 0.86 | MAPT (0.33) | CES2CES1ALDH1A1 | |
| SCHEMBL11714520 | 0.84 | CES2 (0.50) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL21100032 | 0.82 | CES2 (0.36) | CES2CES1HDAC8HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102557867-A | Method for producing low-medium-carbon alcohol | LANZHOU CHEM PHYS INST | 2012-07-11 | — | — | CN | claimed |
| CN-119968452-A | Perfume mixture (VI) | 西姆莱斯股份公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250135059-A1 | COMPOSITIONS COMPRISING FRAGRANCE MATERIALS | THE PROCTER & GAMBLE COMPANY | 2025-05-01 | — | — | US | disclosed |
| EP-4188471-B1 | MICROSPHERE DRUG COATED MEDICAL DEVICES AND METHODS | BIOTRONIK AG (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-11826492-B2 | Intratumoral drug delivery materials and methods for treating breast cancer | BIOTRONIK AG (CH) | 2023-11-28 | — | — | US | disclosed |
| US-11826492-B2 | Intratumoral drug delivery materials and methods for treating breast cancer | BIOTRONIK AG (CH) | 2023-11-28 | — | — | US | disclosed |
| US-20230364016-A1 | INTRACRANIAL DRUG DELIVERY MATERIALS AND METHODS | BIOTRONIK AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230364016-A1 | INTRACRANIAL DRUG DELIVERY MATERIALS AND METHODS | BIOTRONIK AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-0520642-A1 | Resist material and pattern formation process | WAKO PURE CHEMICAL INDUSTRIES LTD (JP) | 1992-12-30 | — | — | EP | disclosed |
| EP-0476865-A1 | Resist material and process for forming pattern using the same | WAKO PURE CHEMICAL INDUSTRIES LTD (JP) | 1992-03-25 | — | — | EP | disclosed |
| EP-0440374-A2 | Chemical amplified resist material | WAKO PURE CHEMICAL INDUSTRIES LTD (JP) | 1991-08-07 | — | — | EP | disclosed |
| US-4871848-A | OIL, GAS WELLS CORROSION INHIBITORS | THE DOW CHEMICAL COMPANY (US) | 1989-10-03 | — | — | US | disclosed |
| US-4740320-A | REACTION OF NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPONENT, KETONE OR ALDEHYDE, AMINE OR POLYAMINE | THE DOW CHEMICAL COMPANY (US) | 1988-04-26 | — | — | US | disclosed |
| US-4724003-A | Asphalt compositions containing anti-stripping additives prepared from hydrocarbyl substituted nitrogen-containing aromatic heterocyclic compounds, aldehydes or ketones and amines | THE DOW CHEMICAL COMPANY (US) | 1988-02-09 | — | — | US | disclosed |
| US-4187251-A | DEODORIZING, ALKYLCYCLOHEXYL ALKYL KETONES | SCHLEPPNIK ALFRED A | 1980-02-05 | — | — | US | disclosed |
| US-4043790-A | 2-OR 4-SUBSTITUTED PYRIDINE METHANE OR PYRIDINE METHANOL, NONHERBICIDAL | ELI LILLY AND COMPANY (US) | 1977-08-23 | — | — | US | disclosed |
| US-3992451-A | IN THE PRESENCE OF FREE RADICAL CATALYSTS, HYDROGEN CHLORIDE, AND CARBON MONOXIDE | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
| US-3974209-A | WATER TREATMENT, COMPLEX METAL IONS | MONSANTO COMPANY (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | CES2 3044/4885CES1 1965/4885HDAC8 899/4885 |
| US-20230364016-A1 | INTRACRANIAL DRUG DELIVERY MATERIALS AND METHODS | PGF, MMP1, NES | CES2 70/4885CES1 2486/4885HDAC8 329/4885 |
| US-11826492-B2 | Intratumoral drug delivery materials and methods for treating breast cancer | EGFR, BRCA1, ERBB2 | CES2 736/4885CES1 2619/4885HDAC8 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.